Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances

With a pair of successful Phase III pivotal studies in hand, the Japanese pharma reports that its nonhormonal hot flash/night sweats candidate demonstrated safety and tolerability over 52 weeks.